Matchpoint Therapeutics is pioneering the development of precision small molecule medicines that leverage covalent bonding to enhance the treatment of immune diseases. The company’s approach focuses on the unique pharmacological advantages of covalent medicines, which form irreversible bonds with specific protein targets. This capability allows for the targeting of a broader range of disease-causing proteins, including those that are typically resistant to traditional small molecule interventions. By utilizing chemoproteomics screening, Matchpoint can identify allosteric, transient, and cryptic binding sites that conventional high-throughput methods might overlook, leading to increased potency and selectivity in drug design.

Additionally, Matchpoint employs advanced machine learning techniques to analyze extensive datasets, guiding their drug discovery efforts by prioritizing targets and informing the design of their covalent screening library. The company is continuously evolving its proprietary library of covalent compounds, which includes a range of candidates from fragments to drug-like compounds. This library is refined using insights gained from predictive algorithms and a deepening understanding of covalency, ultimately aiming to achieve sustained therapeutic efficacy and improved patient outcomes in the treatment of serious immune diseases.

United States

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com. 

Matchpoint Therapeutics

Company Details